Literature DB >> 35184066

Adult Wilms Tumor: Genetic Evidence of Origin of a Subset of Cases From Metanephric Adenoma.

Pedram Argani1,2, Satish K Tickoo3, Andres Matoso1,4, Christine A Pratilas2, Rohit Mehra5, Maria Tretiakova6, Mathilde Sibony7, Alan K Meeker1,2,4, Ming-Tseh Lin1,2, Victor E Reuter3, Jonathan I Epstein1,2,4, Jeffrey Gagan8, Doreen N Palsgrove8.   

Abstract

The genetics of nephroblastoma (Wilms tumor) occurring in adults is largely unknown, as studies have largely been limited to isolated case reports. We, therefore, studied 14 adult Wilms tumors for genetic alterations, using expanded targeted sequencing on 11 cases. The patients ranged from 17 to 46 years of age (mean and median, 31 y), and there were 8 males and 6 females. Five Wilms tumors harbored BRAF V600E mutations. All of these had better-differentiated areas identical to metanephric adenoma, as has previously been described. In 3 such cases, microdissection studies revealed that the BRAF V600E mutation was present in both the metanephric adenoma and Wilms tumor areas; however, additional genetic alterations (including TERT promoter mutations in 2 cases, ASLX1/ATR mutations in 1 other case) were limited to the Wilms tumor component. These findings suggest that the Wilms tumor developed from the metanephric adenoma. Other adult Wilms tumors harbored genetic alterations previously reported in the more common pediatric Wilms tumors, including WT1 mutations (2 cases), ASLX1 mutations (3 additional cases), NSD2 mutation (1 additional case), and 11p loss (3 cases). In summary, a significant subset of adult Wilms tumors (specifically those of epithelial type with differentiated areas) harbor targetable BRAF V600E mutations and appear to arise from metanephric adenomas as a consequence of additional acquired genetic alterations. Other adult Wilms tumors often harbor genetic alterations found in their more common pediatric counterparts, suggesting at least some similarities in their pathogenesis.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35184066      PMCID: PMC9310085          DOI: 10.1097/PAS.0000000000001864

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  69 in total

1.  Disturbed Wnt Signalling due to a Mutation in CCDC88C Causes an Autosomal Recessive Non-Syndromic Hydrocephalus with Medial Diverticulum.

Authors:  A B Ekici; D Hilfinger; M Jatzwauk; C T Thiel; D Wenzel; I Lorenz; E Boltshauser; T W Goecke; G Staatz; D J Morris-Rosendahl; H Sticht; U Hehr; A Reis; A Rauch
Journal:  Mol Syndromol       Date:  2010-09-14

Review 2.  The role of ASXL1 in hematopoiesis and myeloid malignancies.

Authors:  Shuhei Asada; Takeshi Fujino; Susumu Goyama; Toshio Kitamura
Journal:  Cell Mol Life Sci       Date:  2019-03-30       Impact factor: 9.261

3.  Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.

Authors:  John A Kalapurakal; Bin Nan; Patricia Norkool; Max Coppes; Elizabeth Perlman; Bruce Beckwith; Michael Ritchey; Norman Breslow; Paul Grundy; Giulio J D'angio; Daniel M Green; Patrick R M Thomas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

4.  E3 ubiquitin ligase Mule targets β-catenin under conditions of hyperactive Wnt signaling.

Authors:  Carmen Dominguez-Brauer; Rahima Khatun; Andrew J Elia; Kelsie L Thu; Parameswaran Ramachandran; Shakiba P Baniasadi; Zhenyue Hao; Lisa D Jones; Jillian Haight; Yi Sheng; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

Review 5.  Role of PDZ proteins in regulating trafficking, signaling, and function of GPCRs: means, motif, and opportunity.

Authors:  Guillermo Romero; Mark von Zastrow; Peter A Friedman
Journal:  Adv Pharmacol       Date:  2011

6.  Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.

Authors:  Jamal Carter; Li-Hui Tseng; Gang Zheng; Jonathan Dudley; Peter Illei; Christopher D Gocke; James R Eshleman; Ming-Tseh Lin
Journal:  Am J Clin Pathol       Date:  2015-10       Impact factor: 2.493

Review 7.  Adult Wilms' tumor: A monoinstitutional experience and a review of the literature.

Authors:  Monica Terenziani; Filippo Spreafico; Paola Collini; Luigi Piva; Daniela Perotti; Marta Podda; Lorenza Gandola; Maura Massimino; Stefano Cereda; Graziella Cefalo; Roberto Luksch; Michela Casanova; Andrea Ferrari; Daniela Polastri; Pinuccia Valagussa; Franca Fossati-Bellani
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

Review 8.  Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia.

Authors:  Laurel E Black; Jody F Longo; Steven L Carroll
Journal:  Am J Pathol       Date:  2019-07-25       Impact factor: 5.770

9.  Multiple mechanisms of MYCN dysregulation in Wilms tumour.

Authors:  Richard D Williams; Tasnim Chagtai; Marisa Alcaide-German; John Apps; Jenny Wegert; Sergey Popov; Gordan Vujanic; Harm van Tinteren; Marry M van den Heuvel-Eibrink; Marcel Kool; Jan de Kraker; David Gisselsson; Norbert Graf; Manfred Gessler; Kathy Pritchard-Jones
Journal:  Oncotarget       Date:  2015-03-30

10.  Wilms' Tumor in Adults-Conventional and Unconventional Presentations of a Rare Entity with a Review of Literature.

Authors:  Sujata Tripathi; Amit Mishra; Vijay C Popat; Syed Altaf Husain
Journal:  J Kidney Cancer VHL       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.